- Home
- COLL vs CSR Comparison
COLL vs CSR Comparison
Compare COLL & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- CSR
- Stock Information
- Founded
- COLL 2002
- CSR 1970
- Country
- COLL United States
- CSR United States
- Employees
- COLL N/A
- CSR N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- CSR Real Estate Investment Trusts
- Sector
- COLL Health Care
- CSR Real Estate
- Exchange
- COLL Nasdaq
- CSR Nasdaq
- Market Cap
- COLL 1.1B
- CSR 1.1B
- IPO Year
- COLL 2015
- CSR N/A
- Fundamental
- Price
- COLL $37.19
- CSR $74.32
- Analyst Decision
- COLL Strong Buy
- CSR Buy
- Analyst Count
- COLL 6
- CSR 7
- Target Price
- COLL $42.00
- CSR $71.43
- AVG Volume (30 Days)
- COLL 331.7K
- CSR 175.4K
- Earning Date
- COLL 08-08-2024
- CSR 10-28-2024
- Dividend Yield
- COLL N/A
- CSR 4.04%
- EPS Growth
- COLL N/A
- CSR N/A
- EPS
- COLL 2.43
- CSR N/A
- Revenue
- COLL $576,653,000.00
- CSR $258,185,000.00
- Revenue This Year
- COLL $11.23
- CSR N/A
- Revenue Next Year
- COLL $15.15
- CSR $4.65
- P/E Ratio
- COLL $15.32
- CSR N/A
- Revenue Growth
- COLL 7.39
- CSR N/A
- 52 Week Low
- COLL $20.95
- CSR $20.10
- 52 Week High
- COLL $40.95
- CSR $76.16
- Technical
- Relative Strength Index (RSI)
- COLL 54.04
- CSR 56.80
- Support Level
- COLL $37.26
- CSR $74.24
- Resistance Level
- COLL $39.26
- CSR $76.16
- Average True Range (ATR)
- COLL 1.10
- CSR 1.23
- MACD
- COLL -0.01
- CSR -0.11
- Stochastic Oscillator
- COLL 48.38
- CSR 37.63
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and they conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.